MoonLake Immunotherapeutics (MLTX)vsBeOne Medicines AG (ONC)
MLTX
MoonLake Immunotherapeutics
$12.87
-4.74%
HEALTHCARE · Cap: $919.15M
ONC
BeOne Medicines AG
$415.96
-0.96%
HEALTHCARE · Cap: $46.30B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 13.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 70/100 (B-).
MLTX
Avoid28
out of 100
Grade: F
ONC
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MLTX.
Margin of Safety
+81.0%
Fair Value
$1845.68
Current Price
$415.96
$1429.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 33.8% year-over-year
Earnings expanding 212.5% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 22.2%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.2x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : MLTX
The strongest argument for MLTX centers on Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : MLTX
The primary concerns for MLTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 52.2x leaves little room for execution misses.
Key Dynamics to Monitor
MLTX profiles as a value stock while ONC is a growth play — different risk/reward profiles.
MLTX carries more volatility with a beta of 1.13 — expect wider price swings.
ONC is growing revenue faster at 33.8% — sustainability is the question.
ONC generates stronger free cash flow (474M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (70/100 vs 28/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MoonLake Immunotherapeutics
HEALTHCARE · BIOTECHNOLOGY · USA
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug delivery technology. The company is actively developing its lead candidate, a groundbreaking interleukin-17 inhibitor, currently undergoing multiple phases of clinical trials, which has the potential to transform treatment paradigms and improve patient outcomes. With a robust research pipeline and strategic collaborations, MoonLake Immunotherapeutics is poised to meet significant unmet medical needs in the immunotherapy sector, presenting substantial opportunities for institutional investors seeking exposure to the evolving biotech landscape.
BeOne Medicines AG
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?